Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Continuus Pharmaceuticals advances with $5 million in series B funding

by Rick Mullin
September 27, 2019 | A version of this story appeared in Volume 97, Issue 38

 

A photographic closeup of a continuous manufacturing facility.
Credit: Continuus Pharmaceuticals
Continuus says its facility offers in-line continuous solid-liquid clarification.

Continuus Pharmaceuticals, a 2013 spin-off from the Novartis-MIT Center for Continuous Manufacturing, has netted $5 million in its second round of financing. The firm, one of C&EN’s 10 Start-Ups to Watch in 2016, develops continuous technology for drug manufacturing. It’s also developing off-patent drugs in collaboration with pharmacies and hospitals. It recently completed studies for a pilot plant integrating synthesis with formulation in one continuous process line and anticipates starting to build a commercial facility this year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.